Veru Inc.

NASDAQ:VERU

Biotechnology

Healthcare
$3.16 +4.33%

+$0.13 today

Market cap
$50.72M
Beta
-1.13
P/E (TTM)
-4.8
EPS (TTM)
-$0.65
52W Low $2.05High $7.33

Volume 0.34M

Average 1.82M

VERU Operating Income

Profit from core operations after operating expenses, before interest and taxes.

Veru Inc.NASDAQ: VERU

Operating Income · Q2 FY2026 · quarter ended Mar 2026

Operating income remains negative

Q2 FY2026 operating income was -$7.22M, compared with -$8.12M a year earlier. Trailing-twelve-month operating income was -$28.13M.

Context

  • Operating income grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether operating income reaches the consensus estimate from 3 analysts of -$986.99K (+96.0%) for the fiscal year ending Sep 2026, a step up from the +33.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$7.22M-33.1% QoQ
Last fiscal yearSep 2025
-$24.75M+33.0% YoY
LTMMar 2026
-$28.13M+25.0% YoY
Operating Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+11.1%+92.2%+81.0 pp
1 year+33.0%+96.0%+63.1 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Income history

USD · from the income statement

Latest · FY2025
(24.75M) USD
Year-over-year change
+33.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Income vs competitors

How VERU compares with its peers on the latest reported figures

  • VERU's LTM Mar 2026 operating income of -$28.13M is the 5th highest of the 7 companies compared; the peer median is -$20.94M.
  • Its year-over-year change of +25.0% is the 2nd highest of 7, against a peer median of -31.3%.
VERU Competitors Peer median
Operating Income for VERU and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DYAIDyadic International, Inc.LTM Mar 2026-$7.09M -22.7%—238.4%
RNXTRenovoRx, Inc.LTM Mar 2026-$12.87M -10.9%—864.3%
PYPDPolyPid Ltd.LTM Mar 2026-$16.09M +45.1%——
MAIAMAIA Biotechnology, Inc.LTM Mar 2026-$25.79M -39.9%——
VERUVeru Inc.LTM Mar 2026-$28.13M +25.0%——
ANVSAnnovis Bio, Inc.LTM Mar 2026-$41.42M -64.6%——
CELUCelularity Inc.LTM Dec 2025-$61.31M -59.8%—230.9%
Peer median (excluding VERU) -$20.94M-31.3%—238.4%

Competitors are the stored peer set for VERU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Revenue61.26M39.35M16.3M16.89M0
Cost of Revenue13.33M8.76M8.73M11.03M0
Gross Profit47.93M30.59M7.57M5.85M0
Gross Margin78.2%77.7%46.4%34.7%—
Research & Development32.69M70.65M51.2M12.81M15.59M
Selling, General & Admin20.67M43.17M48.06M31.18M19.94M
Operating Expenses53.36M113.81M101.35M42.77M24.75M
Depreciation & Amortization593.87K209.6K269.87K268.18K152.11K
EBITDA9.75M(79.23M)(89.98M)(36.2M)(35.38M)
EBITDA Margin15.9%-201.3%-552.1%-214.4%—
Operating Income12.97M(83.22M)(93.78M)(36.92M)(24.75M)
Operating Margin21.2%-211.5%-575.5%-218.6%—
Interest Income00000
Interest Expense4.89M4.37M2.43M607.47K0
Other Income / Expenses(8.71M)(580.66K)1.11M(160.93K)9.07M
Income Before Tax4.27M(83.8M)(92.67M)(37.08M)(15.68M)
Pre-Tax Margin7.0%-212.9%-568.6%-219.6%—
Income Tax Expense(3.13M)236.4K480.21K725.1K0
Net Income7.39M(83.78M)(93.15M)(37.8M)(22.73M)
Net Margin12.1%-212.9%-571.6%-223.9%—
EPS (Basic)0.97(10.49)(10.96)(2.80)(1.07)
EPS (Diluted)0.88(10.49)(10.96)(2.80)(1.07)
Weighted Avg Shares7.63M8.01M8.5M13.49M14.65M
Weighted Avg Shares (Diluted)8.38M8.01M8.5M13.49M14.65M

Veru Inc.

NASDAQ:VERU

Intrinsic Alpha fair value

Locked

Current Price

$3.16

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.